Comparing Carbetocin and Oxytocin for preventing bleeding in Postpartum wome
Phase 4
Not yet recruiting
- Conditions
- Health Condition 1: - Health Condition 2: O721- Other immediate postpartum hemorrhage
- Registration Number
- CTRI/2024/07/071389
- Lead Sponsor
- Department of Obstetrics and Gynaecology AIIMS Bathinda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Pregnant women at 34 to 40 weeks of gestation undergoing vaginal delivery or cesarean section giving consent to participate
Exclusion Criteria
1.Known case of hypersensitivity to oxytocin and carbetocin13
2.Women with coagulation defects
3.Women with medical conditions (pulmonary, hepatic, renal or cardiovascular disease)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate Carbetocin from Oxytocin in preventing postpartum hemorrhage?
How does Carbetocin's efficacy compare to Oxytocin as a uterotonic agent in postpartum care?
Are there specific biomarkers that predict response to Carbetocin over Oxytocin in preventing PPH?
What adverse events are associated with Carbetocin versus Oxytocin in postpartum women?
What are the current uterotonic drug classes and how does Carbetocin fit within this therapeutic landscape?